Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia

Lifelong treatment of pediatric chronic myeloid leukemia (CML) patients with tyrosine kinase inhibitors (TKIs) can affect their growth and development. For these reasons, clinical trials have explored the feasibility of TKI discontinuation in children with a sufficient TKI response. We evaluated the...

Full description

Bibliographic Details
Main Authors: Yeojae Kim, Seongkoo Kim, Jong Mi Lee, Ari Ahn, Jae Won Yoo, Jae Wook Lee, Bin Cho, Nack-Gyun Chung, Yonggoo Kim, Myungshin Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pediatrics
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitor
BCR-ABL1
digital droplet PCR
molecular response
discontinuation
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.928136/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.928136/full

Similar Items